Seltoplasmid promotes ulcer healing versus placebo for treating patients with chronic limb-threatening ischemia: HOPE CLTI-2 trial.

Authors

Xiao Di, Changwei Liu, Siqiao Sun, Jinbao Qin, Xueli Guo, Yikuan Chen, Xin Li, Hongkun Zhang, Ming Liu, Liu Yang, Hui Zhao, Shaoying Lu, Jingyong Huang, Yunfeng Zhang, Jun Li, Xiaolei Lin, Kai Yao, Jingdong Tang, Jian Wang, Zhanfeng Gao, Jinjun Wang, Xiaojin Huang, Songshan Xu, Yue Liu, Wei Han, Leng Ni, Wei Ye, Yuehong Zheng, Yuexin Chen, Bao Liu

Published in

Molecular therapy : the journal of the American Society of Gene Therapy. Apr 11, 2025. Epub Apr 11, 2025.

Abstract

Intramuscular injection of donaperminogene seltoplasmid (recombinant human hepatocyte growth factor plasmids) represents a gene therapy that treat patients with chronic limb-threatening ischemia (CLTI). The HOPE CLTI-2 trial was a Phase 3, multicenter, double-blind, placebo-controlled study aimed to evaluate the efficacy and safety of seltoplasmid in patients with Rutherford class 5 CLTI. This study did not require participants to be ineligible for revascularization, allowing enrollment of patients with CLTI caused by either atherosclerosis (ASO) or Buerger's disease (TAO). The primary endpoint was the complete ulcer healing rate at 6 months. A total of 242 participants (53.3% ASO versus 46.7% TAO) were enrolled, with 161 receiving seltoplasmid and 81 receiving placebo. Complete ulcer healing was achieved in 70 patients in the seltoplasmid group compared to 15 patients in the placebo group, resulting in an adjusted healing rate difference of 26.1% (95% confidence interval [CI]: 15.1-37.0%; P < 0.001). The hazard ratio for healing was 2.31 (95% CI: 1.32-4.05; P = 0.004). The benefits of seltoplasmid on ulcer healing persisted in both TAO and ASO subgroups. Serious adverse events were rare. Our study demonstrated that seltoplasmid significantly improved ulcer healing rates in patients with Rutherford class 5 CLTI compared to placebo.

PMID:
40221835
Bibliographic data and abstract were imported from PubMed on 14 Apr 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.